HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

propylene diquat (PDQ(+))

RN given in first source; RN given refers to propylene diquat cation radical
Also Known As:
PDQ(+); 1,1'-propylene-2,2'-bipyridilium; 1,1'-propylene-2,2'-bipyridyl; PDQ dibromide; PDQ-radical
Networked: 489 relevant articles (25 outcomes, 68 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Mroz, Thomas E: 19 articles (08/2020 - 01/2015)
2. Benzel, Edward C: 15 articles (01/2020 - 01/2015)
3. Lubelski, Daniel: 13 articles (01/2020 - 01/2015)
4. Miller, Jacob A: 8 articles (05/2019 - 01/2015)
5. Borroni, Serena: 7 articles (01/2021 - 11/2005)
6. Fossati, Andrea: 7 articles (01/2021 - 11/2005)
7. Steinmetz, Michael P: 7 articles (08/2020 - 09/2016)
8. Alvin, Matthew D: 7 articles (01/2020 - 01/2015)
9. Di Carlo, Marco: 6 articles (06/2022 - 01/2019)
10. Salaffi, Fausto: 6 articles (06/2022 - 01/2019)

Related Diseases

1. Pain (Aches)
2. Parkinson Disease (Parkinson's Disease)
3. Fatigue
11/30/2021 - "LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P < 0.0001), motor symptoms (UPDRS-III in "On," -6.5 ± 11.8; P = 0.0002), NMS (NMSS, -35.7 ± 31.1; P < 0.0001), mood (Norris/Bond-Lader VAS, -6.6 ± 21.1; P = 0.0297), fatigue (PFS-16, -0.6 ± 1.0; P = 0.0003), depression (BDI-II, -5.1 ± 9.4; P = 0.0002), anxiety (BAI, -6.2 ± 9.6; P < 0.0001), and patient treatment satisfaction (SATMED-Q, 16.1 ± 16.8; P < 0.0001). "
10/29/2022 - "Apathy (Apathy Scale; p < 0.0001), cognition (PD-Cognitive Rating Scale; p = 0.007), fatigue (Fatigue Severity Scale; p = 0.014), and quality of life (PDQ-39 (p = 0.001) and EUROHIS-QOL8 (p < 0.0001)) improved at 3 weeks as well. "
07/01/2023 - "Potential implementation barriers included alert fatigue and distrust of the risk algorithm (DSC); time constraints, redundancies, and concerns about disclosing uncertainty to patients (DTO); and patient disagreement with the care team's diagnosis (PDQ). "
03/01/2020 - "Significant improvements in physical (walking distance in 2 minutes, number of "Sit To Stands" in 30 seconds, time in seconds taken to "Timed Up and Go," fast gait velocity over 10 m, Berg Balance Scale [BBS]) and psychosocial (quality of life (QoL) [PDQ-39], depression and anxiety [DASS-21], and fatigue [PSF-16]) measures were seen at 6 weeks (all P < .01) with physical improvements sustained at 12 months (all P < .001). "
05/01/2017 - "The following variables were evaluated: functional balance (Berg Scale), fatigue (Fatigue Severity Scale), functional exercise capacity (Six-Minute Walk Test) and quality of life (PDQ-39 Quality of Life Questionnaire). "
4. Personality Disorders (Personality Disorder)
5. Neurobehavioral Manifestations

Related Drugs and Biologics

1. Isoproterenol (Isoprenaline)
2. Adenosine Monophosphate (AMP)
3. rotigotine
4. 4-amino-4'-hydroxylaminodiphenylsulfone (HADS)
5. Microbial Collagenase (Clostridiopeptidase A)
6. Vortioxetine
7. neodymium pyrocatechin disulfonate (NPD)
8. Opioid Analgesics (Opioids)
9. Cytokines
10. C-Reactive Protein

Related Therapies and Procedures

1. Activities of Daily Living (ADL)
2. Transdermal Patch
3. Ligation
4. Biological Therapy
5. Aftercare (After-Treatment)